Atıf Sayısı
1
Görüntüleme
40
İndirme
2
Amaç: Obsesif Kompulsif Bozukluk (OKB) kronik seyirli ve yeti yitimine yol açabilen bir ruhsal bozukluktur. Tedavi konusunda da bazı güçlükler yaşanmakta olup, bilinen tedavi yöntemleri ile hastaların küçük bir yüzdesi asemptomatik hale gelmektedir. OKB tanılı hastaların tedavi seçenekleri arasında öncelikli olarak seçici serotonin geri alım inhibitörleri (SSGI) yer almaktadır. Ancak, çoğu zaman OKB tedavisinde tek başına SSGI ilaçlar yeterli olmayıp, mevcut tedavinin güçlendirilmesi ya da farklı bir antidepresan ilacın eklenmesi tercih edilmektedir. Bu çalışmada SSGI ilaç tedavisine yeterli yanıt alınamayan OKB tanılı hastaların mevcut tedavilerinin aripiprazol, buspiron ve klomipramin ile güçlendirme etkinliğini geriye dönük dosya tarayarak incelemeyi amaçladık. Yöntem: Çalışmamızda, OKB tanısıyla izlenmekte olan ve SSGI’lere yeterli yanıt alınamadığı için tedavilerine aripiprazol, klomipramin ve buspiron ilaçları eklenen hastaların dosyaları geriye dönük olarak incelenmiştir. Dosya kayıtlarından SSGI tedavisinden kısmi yanıt alınan hastaların mevcut tedavisinin aripiprazol (n: 96), buspiron (n: 38) ile güçlendirildiği ve klomipramin (n:76) eklendiği saptandı. Hastaların takibinde rutinde kullanılan Yale-Brown Obsesyon Kompülsiyon Değerlendirme Ölçeği (YBOKÖ), Klinik Global İzlenim Ölçeği (KGİÖ) ve Hamilton Aksiyete Ölçeği (HAÖ) puanları arşivdeki dosyaları incelenerek kayıt edilmiştir. Bulgular: OKB tanılı hastalara verilen aripiprazol, klomipramin ve buspiron ilaçlarının etkinliği KGİ, YBOKÖ ve HAÖ tedavi öncesi ve sonrası değerlere göre bu üç ilacın da etkinliği ile ilgili istatistiksel olarak oldukça anlamlı fark elde edilmiştir (p<0.001). Her üç ilaç kendi arasında karşılaştırıldığında ise aripiprazolun, klomipramin ve buspirondan daha etkin olduğu saptanmıştır. Aripiprazolün tedavi öncesi ve sonrası değerlerine bakıldığında KGİÖ ortalama puanı 5.71±0.58’den 2.98±0.75’e, YBOKÖ ortalama puanı 31.96±2,43’ten 11.77±4.06’ya ve HAÖ ortalama puanı ise 36.58±5.02’den 12.81±4.49’a düştüğü gözlemlenmiştir. Sonuç: Geriye dönük çalışmamızda, aripiprazol, klomipramin, buspiron OKB ekleme tedavisinde etkin bulunmuştur. Çalışmamız bilindiği kadarıyla, aripiprazol, klomipramin ve buspironun SSGI tedavisine eklenmesi ile ilgili sonuçları karşılaştıran ilk çalışmadır. Obsesif kompulsif bozukluk etiyolojik olarak farklılık gösterebildiğinden farklı tedavi yaklaşımlarını gerekli kılmaktadır. Bu nedenle, çalışmamızda farklı etki mekanizmasına sahip ilaç kombinasyonları denenmiştir. Literatürde buspironun OKB tedavisinde veya SSGI’ne ekleme yöntemi kısıtlı sayıda çalışmada görülmektedir. Bu nedenle, buspiron ile tedavi edilmiş geniş hasta grubu olan bir çalışma olması çalışmamızın önemini artırmaktadır.
Obsesive Compulsive Disorder (OCD) is a mental disorder that can lead to chronic visibility and fat loss. There are also some difficulties in the treatment, and a small percentage of patients with known treatments become asymptomatic. The treatment options for patients diagnosed with OCD include primarily selective serotonin recovery inhibitors (SSGIs). However, most times SSGI drugs alone are not enough in the treatment of OCD, and it is preferable to strengthen the existing treatment or add a different antidepressant medicine. In this study, we aimed to examine the effectiveness of enhancing the existing treatments of patients with ADHD diagnosed with aripiprazole, buspirone and clomipramine by scanning back-to-back files. Method: In our study, the files of patients who were monitored with the diagnosis of OCD and who had not received sufficient response to SSGIs added aripiprazole, clomipramine and buspirone medications to their treatments were reviewed backward. It was found that the current treatment of patients receiving partial response from SSGI treatment was enhanced by aripiprazole (n: 96), buspirone (n: 38) and clomipramine (n: 76) added. The Yale-Brown Obsesion Compulsion Assessment Scale (YBOKÖ), the Clinical Global Impact Scale (CGÖ) and the Hamilton Action Scale (HAÖ) scores used in the patient tracking routine have been recorded by examining the files in the archive. Results: The effectiveness of aripiprazole, clomipramine and buspirone medications given to patients diagnosed with ADHD has been statistically significantly differentiated in relation to the effectiveness of these three medications (p<0.001) according to the pre- and post-treatment values of ADHD, ADHD and ADHD. When compared each of the three medications, aripiprazole has been found to be more effective than clomipramine and buspirine. With regard to the pre- and post-treatment values of Aripiprazole, the average CGIO score was observed from 5.71±0.58 to 2.98±0.75; the average CGIO score was observed from 31.96±2.43 to 11.77±4.06 and the average CGIO score was observed from 36.58±5.02 to 12.81±4.49. The result: In our backward study, aripiprazole, clomipramine, buspirone have been effective in the treatment of the addition of OKB. As far as our study is known, it is the first study comparing the results related to the addition of aripiprazole, clomipramine and buspirone to the SSGI treatment. Obsessive compulsive disorder is the one that requires different therapeutic approaches, since it can be etiologically different. Therefore, we have tested medication combinations with different mechanisms of action in our study. In literature, the method of adding buspirone to OKB or SSGI is seen in a limited number of studies. Therefore, the importance of our study to be a study of a wide group of patients treated with buspiron increases.
Aim: Obsessive Compulsive Disorder (OCD) is a chronic disorder that can lead to disability. There are some difficulties in treatment, and a small percentage of patients become asymptomatic with known treatment methods. Among the treatment options of patients with OCD, selective serotonin reuptake inhibitors (SSRI) are primarily involved. However, most of the time, SSRI drugs alone are not sufficient in the treatment of OCD, it is preferred to strengthen the current treatment or to add a different antidepressant drug. In this study, we aimed to investigate the efficacy of aripiprazole, buspirone and clomipramine in patients with OCD who were unable to respond adequately to SSRI drug therapy. Method: In our study, the files of the patients who were followed with the diagnosis of OCD and who were added aripiprazole, clomipramine and buspirone drugs to their treatment because of insufficient response to SSRIs were examined retrospectively. It was determined that the current treatment of patients who received partial response from SSRI treatment was augmened with aripiprazole (n: 96), buspirone (n: 38) and clomipramine (n: 76) was added. Yale-Brown Obsessive Compulsive Evaluation Scale (YBOCS), Clinical Global Impression Scale (CGI) and Hamilton Anxiety Scale (HAS) scores were used to evaluate the patients in the follow-up. Results: The efficacy of aripiprazole, clomipramine and buspirone medications given to patients with OCD was statistically significant (p <0.001). Aripiprazole was found to be slightly more effective than clomipramine and buspirone. When the pre- and post-treatment values of aripiprazole were evaluated, it was observed that the mean score of CGI declined from 5.71 ± 0.58 to 2.98 ± 0.75, YBOCS scores declined from 31.96 ± 2.43 to 11.77 ± 4.06 and HAS score declined from 36.58 ± 5.02 to 12.81 ± 4.49. Conclusion: In our retrospective study, aripiprazole, clomipramine and buspirone were found to be effective in the treatment of OCD. As far as we know, our study is the first study to compare the results of aripiprazole, clomipramine and buspirone in addition to the treatment of SSRI. Therefore, in our study drug combinations with different mechanism of action have been tried. In the literature, the method of augmentation of buspirone in OCD or SSRI is limited in a limited number of studies. Therefore, a study with a large group of patients treated with buspirone increases the importance of our study.
Alan : Sağlık Bilimleri
Dergi Türü : Uluslararası
Makale Detay 
Atıf Yapanlar
Benzer Makaleler
PDF Görüntüle
Dergi Bilgisi
Eseri Dinleyin
Bu Sayfayı Yazdırın
Paylaş
Mendeley
